Keros Therapeutics, Inc. KROS
At closeNov 6, 2026, 4:26 PM EST
After hours · Nov 6, 4:26 PM ET
- YTD
- -54.03%
- 1 year
- -42.12%
- Market cap
- 185.58M
- Revenue (ttm)
- 651.00K
- EPS (ttm)
- -3.22
- Shares out
- 40.51M
- Forward P/E
- -3.00
- YTD return
- -54.03%
- 1-year return
- -42.12%
- Volume
- 192.04K
- Avg volume
- 180.32K
- Open
- 9.74
- Previous close
- 9.45
- Day's range
- 9.26 – 9.96
- 52-week range
- 9.36 – 21.84
- Beta
- 1.24
- Analysts
- Buy
- Price target
- 43.55 (+365.2%)
- Earnings date
- Aug 7, 2024
5D -1.76 (-15.83%)
Key statistics
- Enterprise value
- 178.44M
- PEG ratio
- 0.00
- Price / sales
- 1065.26
- Price / book
- 1.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 4750.00%
- Free cash flow
- -89.32M
- Total cash
- 530.68M
- Total debt
- 19.29M
- Return on equity
- -43.82%
- Short % of float
- 7.39%
- 50-day average
- 55.00
- 200-day average
- 53.85
Analyst view
Consensus: buy
- Target (low)
- 23.00
- Target (mean)
- 43.55
- Target (high)
- 76.00
- Strong buy3
- Buy8
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.51.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -1.26 | -1.41 | -0.15 | -11.90% |
| Aug 7, 2024 | Jun 1, 2024 | -1.23 | -1.25 | -0.02 | -1.63% |
| Aug 7, 2024 | Jun 1, 2024 | -1.23 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -1.31 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -1.31 | -1.21 | +0.10 | +7.63% |
| Feb 28, 2024 | Dec 1, 2023 | -1.38 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | Truist Securities | main | Buy | Buy |
| Dec 16, 2024 | Oppenheimer | main | Outperform | Outperform |
| Dec 16, 2024 | Guggenheim | down | Buy | Neutral |
| Dec 13, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | William Blair | down | Outperform | Market Perform |
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kerostx.com
News
Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial 
Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy 
Keros Therapeutics Reveals $5M Share Repurchase Authorization - Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18
Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate 
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial 
Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate - Keros Therapeutics Presents Additional Data From Its Phase 1 Clinical Study Of Rinvatercept In Health Volunteers At 2026 Muscular Dystrophy Association Clinical & Scientific Conference
- Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $20
- CORRECTION: Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $385.000K Miss $2.757M Estimate
Your note
Sign in to keep a note on KROS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GORDON CARL L | Director | Sale | Aug 12, 2024 | 0 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Sale | Aug 12, 2024 | 0 |
| REGNANTE KEITH C | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 2, 2023 | 0 |
| SEEHRA JASBIR | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 6, 2023 | 252,856 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.09% | 4,899,134 | 83.87M | Sep 29, 2024 |
| Blackrock Inc. | 6.50% | 2,632,608 | 45.07M | Sep 29, 2024 |
| Alkeon Capital Management LLC | 4.68% | 1,897,601 | 32.49M | Sep 29, 2024 |
| Vanguard Group Inc | 4.58% | 1,856,418 | 31.78M | Sep 29, 2024 |
| Darwin Global Management, Ltd. | 3.76% | 1,523,732 | 26.09M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 3.74% | 1,514,505 | 25.93M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 961,347 | 16.46M | Sep 29, 2024 |
| ACAP Strategic Fund | 2.31% | 933,991 | 15.99M | Sep 29, 2024 |
| Price (T.Rowe) New Horizons Fund | 2.17% | 877,880 | 15.03M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.87% | 756,550 | 12.95M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.63% | 661,229 | 11.32M | Oct 30, 2024 |
| Fidelity Select Portfolios - Health Care | 1.60% | 650,000 | 11.13M | Oct 30, 2024 |